Gene-editing by CRISPR–Cas9 in combination with anthracycline therapy via tumor microenvironment-switchable, EGFR-targeted, and nucleus-directed nanoparticles for head and neck cancer suppression-Reference-Cited by-同舟云学术

Gene-editing by CRISPR–Cas9 in combination with anthracycline therapy via tumor microenvironment-switchable, EGFR-targeted, and nucleus-directed nanoparticles for head and neck cancer suppression

Published:2021 Issue:9 Volume:6 Page:729-743
ISSN:2055-6756
Container-title:Nanoscale Horizons
language:en
Short-container-title:Nanoscale Horiz.

Author:

Wang Chen-Shen¹²,Chang Chih-Hsien¹²,Tzeng Tsai-Yu³,Lin Anya Maan-Yuh¹²⁴⁵,Lo Yu-Li¹²⁴⁶^ORCID

Affiliation:

1. Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan

2. Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan

3. Cancer Progression Research Center, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan

4. Faculty of Pharmacy, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan

5. Department of Medical Research, Taipei Veterans General Hospital, Taipei 11221, Taiwan

6. Center for Advanced Pharmaceutics and Drug Delivery Research, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan

Abstract

The smart nanoparticles may provide a combinatorial spatiotemporal platform against tumors for chemotherapy and the CRISPR/Cas gene-editing system with the advantages of a tumor pH response, active EGFR targeting, and nuclear localization.

Funder

Ministry of Science and Technology, Taiwan

University System of Taiwan

Cheng Hsin General Hospital Foundation

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science

Link

http://pubs.rsc.org/en/content/articlepdf/2021/NH/D1NH00254F

Reference41 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries